Suppliers / Bristol-Myers Squibb

Bristol-Myers Squibb

United States BMY 32,500 employees Updated 9 July 2026

Bristol-Myers Squibb is an API and finished-dose manufacturer based in United States. It appears in 5,468 regulatory filings across 49 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, DIGEMAPS (DO) and EMA. Its GMP standing is certified by MHRA (UK), EMA and UZPHARM (UZ), among 11 authorities. Its most recent recorded inspection, by US FDA, closed on 18 July 2025 as VAI. Customs aggregates show $9K of exports covering 962 molecules to 5 destinations in 2025.

0
active US DMFs
0
valid CEPs
12
registered plants
5,468
filings across 49 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 18 July 2025 VAI US FDA
  • 6 December 2024 VAI US FDA
  • 24 September 2024 NAI US FDA
  • 6 September 2024 NAI US FDA
  • 31 January 2024 NAI US FDA
  • 26 September 2023 NAI US FDA
  • 20 September 2023 VAI US FDA
  • 16 June 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Manati, United Arab Emirates Not on file
Manati, United Arab Emirates Not on file
Utrecht, United Arab Emirates Not on file
Boudry, United Arab Emirates Not on file
Quebec, United Arab Emirates Not on file
QQuebec, United Arab Emirates Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Saxagliptin SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Acetaminophen finished dose Acetylcysteine finished dose Allopurinol finished dose Amikacin finished dose Amiodarone finished dose Amitriptyline finished dose Ampicillin finished dose Apixaban finished dose Aripiprazole finished dose Atazanavir finished dose Atenolol finished dose Azacitidine finished dose
Show 121 more molecule pages
Aztreonam finished dose Benzylpenicillin finished dose Betahistine finished dose Bicalutamide finished dose Buspirone finished dose Captopril finished dose Carbidopa finished dose Carbocisteine finished dose Carboplatin finished dose Carmustine finished dose Carvedilol finished dose Cefadroxil finished dose Cefazolin finished dose Cefepime finished dose Celecoxib finished dose Cephalexin finished dose Chlorphenamine finished dose Chlorpheniramine finished dose Cholestyramine finished dose Ciclesonide finished dose Cimetidine finished dose Cinacalcet finished dose Cisplatin finished dose Citalopram finished dose Clopidogrel finished dose Cloxacillin finished dose Cobicistat finished dose Cyclophosphamide finished dose Daclatasvir finished dose Dapagliflozin finished dose Dapagliflozin Propanediol finished dose Dasatinib finished dose Desloratadine finished dose Deucravacitinib finished dose Dextromethorphan finished dose Diazepam finished dose Digoxin finished dose Dolutegravir finished dose Domperidone finished dose Doxazosin Mesilate finished dose Doxorubicin finished dose Doxylamine finished dose Econazole finished dose Efavirenz finished dose Emtricitabine finished dose Enalapril finished dose Enoxaparin finished dose Entecavir finished dose Erythromycin finished dose Esmolol finished dose Etoposide finished dose Exemestane finished dose Ferrous finished dose Finasteride finished dose Fluphenazine finished dose Flurbiprofen finished dose Gatifloxacin finished dose Gliclazide finished dose Guaifenesin finished dose Hydroxychloroquine finished dose Hydroxyurea finished dose Hydroxyzine finished dose Indomethacin finished dose Irbesartan finished dose Ivabradine finished dose Ketorolac Tromethamine finished dose Labetalol finished dose Lactulose finished dose Lamivudine finished dose Lamotrigine finished dose Lenalidomide finished dose Letrozole finished dose Levocetirizine finished dose Levodopa finished dose Lisinopril finished dose Loperamide finished dose Mavacamten finished dose Megestrol finished dose Metformin finished dose Metoclopramide finished dose Metoprolol finished dose Morphine finished dose Nadolol finished dose Naltrexone finished dose Nitrofurantoin finished dose Nitroglycerin finished dose Norethisterone finished dose Nystatin finished dose Oxacillin finished dose Oxytetracycline finished dose Ozanimod finished dose Paclitaxel finished dose Paracetamol finished dose Paroxetine finished dose Phenobarbital finished dose Pomalidomide finished dose Pravastatin finished dose Propranolol finished dose Rabeprazole finished dose Raloxifene finished dose Ramipril finished dose Ranitidine finished dose Rasagiline finished dose Rivastigmine finished dose Saxagliptin API Solifenacin finished dose Sotalol finished dose Spironolactone finished dose Succinylcholine finished dose Telmisartan finished dose Tenofovir Alafenamide finished dose Tenofovir Disoproxil finished dose Tetracycline finished dose Trazodone finished dose Triamcinolone finished dose Triamcinolone Acetonide finished dose Trimethoprim finished dose Venlafaxine finished dose Warfarin finished dose Zolpidem finished dose Zopiclone finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 1,908 None
DIGEMAPS (DO) 458 None
EMA 339 10
US FDA 305 4
INHRR (VE) 270 None
AIFA (IT) 204 None
MHRA (UK) None 14
UZPHARM (UZ) None 5
MFDS (Korea) None 4
HSA (SG) None 3
NAFDAC (NG) None 3
ANVISA (Brazil) None 2
COFEPRIS (MX) None 2
EAEU_EEC None 1
EDA (EG) None 1

Scale

Year Revenue Exports Destinations
2025 $48.2B $9K 5
2024 $48.3B $7K 6
2023 $45.0B $794 4
2022 Not reported $2K 2

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Bristol-Myers Squibb

Does Bristol-Myers Squibb hold a US DMF or a CEP?
No active US drug master file or valid CEP is on record for Bristol-Myers Squibb. It does have 5,468 filings with 49 regulators, so it is registered, just not with the two strong registers buyers usually screen on.
How did Bristol-Myers Squibb's last inspection go?
The most recent inspection on record closed on 18 July 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 8 inspections are on file.
Where does Bristol-Myers Squibb manufacture?
12 registered sites are on record, in United Arab Emirates, Switzerland and United Kingdom (Manati, Utrecht and Boudry among others). Every site is listed on this page with the register it came from.
What does Bristol-Myers Squibb make?
1 molecule is on record against Bristol-Myers Squibb, including Saxagliptin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Bristol-Myers Squibb's GMP?
Current GMP certificates are on record from MHRA (UK), EMA, UZPHARM (UZ), US FDA, MFDS (Korea) and 6 more. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Bristol-Myers Squibb comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 80 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 18 July 2025.

Comparable suppliers

Apitoria Pharma shares 1 molecule Dr Reddy's Laboratories shares 1 molecule Alivus Life Sciences shares 1 molecule Matrix Pharmacorp shares 1 molecule Raks Pharma shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported